The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2021 | The future of MPN therapy
Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, comments on the direction in which myeloproliferative neoplasm (MPN) therapy is currently headed and the implications for MPN patients. Dr Kuykendall talks on the currently approved treatments ruxolitinib and fedratinib, and the patient subgroups whose clinical needs are not well served by JAK inhibition. Dr Kuykendall also talks about a potential shift in research focus which may be witnessed in the coming years, centered around early intervention in the chronic phases of MPNs to halt disease progression. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Andrew Kuykendall, MD, has received research fees from Protagonist, Sierra and Prelude; has participated in steering committees for Constellation and Protagonist; has participated in consultancy for Protagonist; has received honoraria from and/or participated in advisory boards with Pharmaessentia, BMS/Celgene, Incyte, Novartis, Abbvie and Blueprint; and has participated in speakers’ bureau for Novartis, Blueprint and BMS/Celgene.
